Technology | PET Imaging | December 05, 2018

Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET

Artificial intelligence-based technology allows faster PET scans while enhancing image quality

Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET

December 5, 2018 — Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle Medical also recently secured approval to affix the CE Mark on SubtlePET to begin marketing in the European Economic Area without restrictions.

SubtlePET’s artificial intelligence (AI)-powered technology allows hospitals and imaging centers to enhance images from faster positron emission tomography (PET) scans, leading to an improved patient experience during nuclear imaging procedures, while boosting exam throughput and provider profitability. SubtlePET is currently in pilot clinical use in multiple university hospitals and imaging centers in the U.S. and abroad.

“Focusing Subtle Medical's SubtlePET AI platform on faster image acquisition, we have been able to dramatically increase PET scan efficiency and provide a superior patient experience. SubtlePET  technology allows us to scan a patient four times faster than normal, yet maintain equal image quality, not otherwise impacting work flow,” said Michael Brant-Zawadzki, M.D., FACR, Hoag Hospital, Newport Beach, Calif. “This creates immediate ROI [return on investment] benefit for our hospital and a compelling value proposition. I’m looking forward to seeing more groundbreaking technology from the Subtle team.”

Subtle Medical’s AI solution:

  • Enables completion of more exams in a day compared to conventional PET imaging without the need for capital expenditures;
  • Reduces patient time in the scanner; and
  • Helps hospitals and imaging centers enhance their bottom line in today’s competitive healthcare environment.  

The company’s technology utilizes deep learning algorithms that integrate seamlessly with any OEM scanner and picture archiving and communication system (PACS) to enhance images during acquisition, without any interruption or alteration in the imaging specialists’ workflow.  SubtlePET delivers a significant improvement in the image quality of noisy images resulting from shorter scans, which is particularly beneficial for children and those undergoing repeat PET exams.

SubtlePET is the first product in Subtle Medical’s growing portfolio of new AI technologies to receive FDA clearance. The company is developing additional products to be submitted for FDA clearance.  A second product currently undergoing clinical evaluation is SubtleMR, which allows imaging centers to significantly accelerate magnetic resonance imaging (MRI) scans using the company’s AI solutions. SubtleGAD is also being developed to reduce gadolinium dosage during imaging procedures.

For more information: www.subtlemedical.com

Related Content

Selfied might be used with AI to identify patients with heart disease. Getty Images

Getty Images

News | Artificial Intelligence | August 24, 2020
August 24, 2020 — Sending a photo selfie to the doctor could be a cheap and simple way of detecting heart disease usi
aption Health a leader in medical AI technology, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an updated version of Caption Interpretation, which uses artificial intelligence (AI) to enable clinicians to obtain quick, easy and accurate measurements of cardiac ejection fraction (EF) at the point of care.

Caption Health a leader in medical AI technology, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an updated version of Caption Interpretation, which uses artificial intelligence (AI) to enable clinicians to obtain quick, easy and accurate measurements of cardiac ejection fraction (EF) at the point of care.

News | Artificial Intelligence | August 19, 2020
August 19, 2020 — Caption Health a leader in medical AI technology, has received U.S.
In February 2020, the U.S. Food and Drug Administration (FDA) cleared artificial intelligence software to assist in the acquisition of cardiac ultrasound images. The Caption Guidance software from Caption Health is an accessory to compatible diagnostic ultrasound systems and uses artificial intelligence to help the user capture images of a patient’s heart that are of acceptable diagnostic quality. It is aimed at point of care ultrasound (POCUS) exams, where users may not be regular sonographers.

In February 2020, the U.S. Food and Drug Administration (FDA) cleared artificial intelligence software to assist in the acquisition of cardiac ultrasound images. The Caption Guidance software from Caption Health is an accessory to compatible diagnostic ultrasound systems and uses artificial intelligence to help the user capture images of a patient’s heart that are of acceptable diagnostic quality. It is aimed at point of care ultrasound (POCUS) exams, where users may not be regular sonographers.

Feature | Artificial Intelligence | August 18, 2020 | Dave Fornell, Editor
The No.
An example of DiA'a automated ejection fraction AI software on the GE vScan POCUS system at RSNA 2019.

An example of DiA'a automated ejection fraction AI software on the GE vScan POCUS system at RSNA 2019.

News | Artificial Intelligence | May 26, 2020
May 26, 2020 — DiA Imaging Analysis, a provider of AI based ultrasound analysis solutions, said it received a governm
A list of all the abnormalities the AI model classifies. This illustration only shows three representative leads (DII, V1 and V6).Fig. This is Figure 1 from the Nature Communications article.

A list of all the abnormalities the AI model classifies. This illustration only shows three representative leads (DII, V1 and V6).Fig. This is Figure 1 from the Nature Communications article.

News | Artificial Intelligence | May 19, 2020
May 19, 2020 — Artificial inte...
TeraRecon will accelerate innovation in its advanced visualization and AI platforms for image-related decision support to clinical specialists

TeraRecon's End-to-End AI Ecosystem

News | Artificial Intelligence | March 04, 2020
March 4, 2020 — SymphonyAI Group, an operating group of lea